BACKGROUND: The main aims of the present study were to develop a pharmacogenetic-based warfarin dosing algorithm and to validate it in a highly admixed population. MATERIALS & METHODS: We included two patient cohorts treated with warfarin (first cohort, n = 832; and second cohort, n = 133). RESULTS: Our algorithm achieved a determination coefficient of 40% including the variables age, gender, weight, height, self-declared race, amiodarone use, enzyme inducers use, VKORC1 genotypes and predicted phenotypes according to CYP2C9 polymorphisms. CONCLUSION: Data suggest that our developed algorithm is more accurate than the IWPC algorithm when the application is focused on patients from the Brazilian population. Population-specific derivation and/or calibration of warfarin dosing algorithms may lead to improved performance compared with general use dosing algorithms currently available. Original submitted 26 November 2014; Revision submitted 9 April 2015.
BACKGROUND: The main aims of the present study were to develop a pharmacogenetic-based warfarin dosing algorithm and to validate it in a highly admixed population. MATERIALS & METHODS: We included two patient cohorts treated with warfarin (first cohort, n = 832; and second cohort, n = 133). RESULTS: Our algorithm achieved a determination coefficient of 40% including the variables age, gender, weight, height, self-declared race, amiodarone use, enzyme inducers use, VKORC1 genotypes and predicted phenotypes according to CYP2C9 polymorphisms. CONCLUSION: Data suggest that our developed algorithm is more accurate than the IWPC algorithm when the application is focused on patients from the Brazilian population. Population-specific derivation and/or calibration of warfarin dosing algorithms may lead to improved performance compared with general use dosing algorithms currently available. Original submitted 26 November 2014; Revision submitted 9 April 2015.
Authors: Letícia C Tavares; Nubia E Duarte; Leiliane R Marcatto; Renata A G Soares; Jose E Krieger; Alexandre C Pereira; Paulo Caleb Junior Lima Santos Journal: Eur J Clin Pharmacol Date: 2018-07-26 Impact factor: 2.953
Authors: Marcus Fernando S Praxedes; Maria Auxiliadora P Martins; Aline O M Mourão; Karina B Gomes; Edna A Reis; Renan P Souza; Emílio Itamar F Campos; Daniel D Ribeiro; Manoel Otávio C Rocha Journal: Eur J Clin Pharmacol Date: 2019-11-12 Impact factor: 2.953
Authors: Innocent G Asiimwe; Eunice J Zhang; Rostam Osanlou; Amanda Krause; Chrisly Dillon; Guilherme Suarez-Kurtz; Honghong Zhang; Jamila A Perini; Jessicca Y Renta; Jorge Duconge; Larisa H Cavallari; Leiliane R Marcatto; Mark T Beasly; Minoli A Perera; Nita A Limdi; Paulo C J L Santos; Stephen E Kimmel; Steven A Lubitz; Stuart A Scott; Vivian K Kawai; Andrea L Jorgensen; Munir Pirmohamed Journal: Clin Pharmacol Ther Date: 2020-01-28 Impact factor: 6.875
Authors: Justin B Kaye; Lauren E Schultz; Heidi E Steiner; Rick A Kittles; Larisa H Cavallari; Jason H Karnes Journal: Pharmacotherapy Date: 2017-09-06 Impact factor: 4.705